RSCM
LGND icon

Rock Springs Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Rock Springs Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-80,150
Closed -$5.29M – 152
2017
Q1 		$5.29M Sell
80,150
-32,060
-29% -$2.11M 0.31% 88
2016
Q4 		$7.11M Buy
112,210
+8,015
+8% +$506K 0.48% 60
2016
Q3 		$6.63M Buy
+104,195
New +$7.65M 0.42% 71

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Rock Springs Capital Management's LGND Position: Q2 2017 in Review

Rock Springs Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2017, closing a stake of 80,150 shares — an estimated $5.29M sold.

Rock Springs Capital Management first reported a position in LGND in Q3 2016 and held it in 3 quarters. The position peaked at $7.11M in Q4 2016. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

  • Rock Springs Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Rock Springs Capital Management sold 80,150 Ligand Pharmaceuticals shares in Q2 2017, an estimated $5.29M.
  • Rock Springs Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Rock Springs Capital Management's Ligand Pharmaceuticals position peaked at $7.11M in Q4 2016.
  • 265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Rock Springs Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.